Table 1.
Demographic and clinical data for cases and controls.
| Characteristic | Controls (N = 18) | Sarcoidosis subjects (N = 54) | p-Value |
|---|---|---|---|
| Age-yr Mean Range | 52 37-74 | 50 31-75 | 0.523 |
| Gender - no.(%) Female | 13 (72) | 40 (74) | 1.000 |
| Ancestry - no. (%) African American European American Hispanic | 13 (72) 5(27) 0 | 43 (80) 10 (10) 1 (2) | 0.611 |
| Active Smoking - no. (%) Yes No Unknown | 3(17) 13 (72) 2(11) | 3 (5) 50 (93) 1(2) | 0.100 |
| Immunosuppression a - no. (%) Yes No Unknown | - | 31 (57) 22 (41) 1 (2) | - |
| Years since diagnosis - no. (%) <2 years (acute disease) >2 years (chronic disease) | - | 2 (4) 52 (96) | - |
| Sub-phenotype no. (%) Lofgren’s syndrome Fibrotic pulmonary sarcoidosis Non-fibrotic pulmonary sarcoidosis | - | 0(0) 19 (35) 21 (39) | - |
a
Preclnisone =10 mg/daily, or any other immunosuppressive therapy.